Who are Maseptol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inomax, Estrobene, Naphcon Forte, Infuvite Adult, Cliquinol, Addiclenz.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylparaben.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Maseptol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maseptol (methylparaben) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Standardized Chemical Allergen. Area: Metabolic.

unknown Standardized Chemical Allergen Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14 Metabolic Live · refreshed every 30 min

Target snapshot

Maseptol (methylparaben). Maseptol works by binding to carbonic anhydrase 7, a protein involved in various cellular processes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maseptol TARGET	methylparaben		unknown	Standardized Chemical Allergen	Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14
Inomax	NITRIC OXIDE	Vero Biotech Inc	marketed	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Estrobene	DIETHYLSTILBESTROL	Tablicaps	marketed	Standardized Chemical Allergen [EPC]	Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3	1973-01-01
Naphcon Forte	NAPHAZOLINE	Novartis	marketed	Non-Standardized Chemical Allergen [EPC]	Alpha-2A adrenergic receptor	1971-01-01
Infuvite Adult	Nicotinamide	Pfizer	marketed	Standardized Chemical Allergen [EPC]	NAD-dependent protein deacetylase sirtuin-2	1953-01-01
Cliquinol	CLIOQUINOL		marketed	Standardized Chemical Allergen [EPC]	Amyloid beta A4 protein	1934-01-01
Addiclenz	ASPARTAME	Deseret Biologicals, Inc.	marketed	Standardized Chemical Allergen [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Standardized Chemical Allergen class)

· 7 drugs in this class
HITEC-Institute of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maseptol — Competitive Intelligence Brief. https://druglandscape.com/ci/methylparaben. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing